Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | US/EU | 2016
The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig. Although these agents have improved the treatment outcomes considerably, most patients eventually stop responding and ultimately die of their disease. The currently available second-line CLL therapies are moderately satisfying in terms of efficacy, safety and tolerability, convenience of administration, and non-clinical factors, yet the remaining unmet need for more-efficacious and better-tolerated therapies presents a significant commercial opportunity
Related Market Assessment Reports
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
